Advertisement

Reactions Weekly

, Volume 1731, Issue 1, pp 83–83 | Cite as

Cladribine/famciclovir/valaciclovir

Various toxicities: 4 case reports
Case report
  • 12 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a study of 71 patients, four patients including a 39-year-old man [not all ages and sexes stated] received off-label SC cladribine [Litak] and developed lymphopenia. In addition to this, one patient developed nausea during treatment with famciclovir, and one patient developed headache on famciclovir and vertigo during treatment with valaciclovir [durations of treatments to reactions onsets not stated; not all routes, dosages and outcomes stated].

Patient 1: The patient who had progressive multiple sclerosis, started receiving off-label treatment with SC cladribine. During the first week of treatment, the patient received SC cladribine 10mg on day 1, 2 and 3. Four weeks later, differential white cell counts were obtained, and depending upon the total lymphocyte count,another...

Reference

  1. Mao Z, et al. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. Multiple Sclerosis and Related Disorders 27: 247-253, Jan 2019. Available from: URL: http://doi.org/10.1016/j.msard.2018.11.001 - ChinaCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations